A Comparison of Rocuronium 0.6 mg/kg and Remifentanil 2 µg/kg in Elderly Patients Over 80 Years
Status:
Completed
Trial end date:
2020-12-13
Target enrollment:
Participant gender:
Summary
The number of elderly patients above 80 years is increasing and a large proportion of these
patients will require surgery and anesthesia.
During anesthesia neuromuscular blocking agents (NMBA) are administered to facilitate
intubating conditions and reduce the trauma to the larynx and vocal cords. There is a risk of
residual neuromuscular block when using NMBAs like rocuronium.
Remifentanil is a fentanyl analogue commonly used for induction since it also facilitates
intubation. There is no risk of residual neuromuscular block, nonetheless circulatory side
effects have been seen.
It is unknown which is superior concerning intubating conditions in elderly patients.
Therefore, the aim of this study is to determine the effect on intubating conditions and
laryngeal morbidity after either rocuronium 0.6 mg/kg or remifentanil 2 µg/kg in patients
with age ≥ 80 years. The hypothesis of this study is that rocuronium 0.6 mg/kg provides a
higher proportion with excellent intubating conditions compared to remifentanil 2 µg/kg.